Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial

The Lancet

Volumn 388, Issue 10063, 2016, Pages 2997-3005

  Robertson, John F R ^a   Bondarenko, Igor M ^b   Trishkina, Ekaterina ^c   Dvorkin, Mikhail ^d   Panasci, Lawrence ^e   Manikhas, Alexey ^f   Shparyk, Yaroslav ^g   Cardona Huerta, Servando ^h   Cheung, Kwok Leung ^a   Philco Salas, Manuel Jesus ⁱ   Ruiz Borrego, Manuel ^j   Shao, Zhimin ^k   Noguchi, Shinzaburo ^l   Rowbottom, Jacqui ^m   Stuart, Mary ^m   Grinsted, Lynda M ^m   Fazal, Mehdi ^m   Ellis, Matthew J ⁿ  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b Dnipropetrovsk State Medical Academy   (Ukraine)

^c Leningrad Regional Oncology Dispensary   (Russian Federation)

^d Clinical Cardiological Dispensary   (Russian Federation)

^e MCGILL UNIVERSITY   (Canada)

^f City Clinical Oncology Dispensary   (Russian Federation)

^g Chemotherapy Department   (Ukraine)

^h SCHOOL OF ENGINEERING AND SCIENCES   (Mexico)

ⁱ Instituto Oncológico de Lima   (Peru)

^j HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^k FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^l OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^m ASTRAZENECA   (United Kingdom)

ⁿ BAYLOR COLLEGE OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANASTROZOLE; ASPARTATE AMINOTRANSFERASE; FULVESTRANT; HORMONE RECEPTOR; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; AROMATASE INHIBITOR; ESTRADIOL; ESTROGEN RECEPTOR; NITRILE; TRIAZOLE DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACKACHE; CANCER CHEMOTHERAPY; CANCER PATIENT; CONSTIPATION; CONTROLLED STUDY; COUGHING; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FEMALE; HOT FLUSH; HUMAN; HYPERTENSION; HYPERTRANSAMINASEMIA; INSOMNIA; LIMB PAIN; MAJOR CLINICAL STUDY; METASTATIC BREAST CANCER; MYALGIA; NAUSEA; PERIPHERAL EDEMA; PHASE 3 CLINICAL TRIAL; POST TREATMENT SURVIVAL; POSTMENOPAUSE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; VERY ELDERLY; ANALOGS AND DERIVATIVES; BREAST; BREAST NEOPLASMS; CLINICAL TRIAL; DISEASE FREE SURVIVAL; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PATHOLOGY;

ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; ESTRADIOL; FEMALE; HUMANS; MIDDLE AGED; NITRILES; POSTMENOPAUSE; RECEPTORS, ESTROGEN; TRIAZOLES;

EID: 85006272139     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(16)32389-3     Document Type: Article

References (25)

1. 1 National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology Version.2.2015: Breast Cancer. http://www.nccn.org/professionals/physician_gls/PDF/breast.pdf, 2015 (accessed July 23, 2016).
2. 2 Rugo, HS, Rumble, RB, Macrae, E, et al. Endocrine therapy for hormone receptor-positive metastatic breast cancer: American Society of Clinical Oncology Guideline. J Clin Oncol 34 (2016), 3069–3103.
3. 3 Cardoso, F, Costa, A, Norton, L, et al. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). Breast 23 (2014), 489–502.
4. 4 Nabholtz, JM, Buzdar, A, Pollak, M, et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol 18 (2000), 3758–3767.
5. 5 Bonneterre, J, Buzdar, A, Nabholtz, JM, et al. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer 92 (2001), 2247–2258.
6. 6 Mouridsen, H, Gershanovich, M, Sun, Y, et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 19 (2001), 2596–2606.
7. 7 Mouridsen, H, Gershanovich, M, Sun, Y, et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 21 (2003), 2101–2109.
8. 8 Paridaens, RJ, Dirix, LY, Beex, LV, et al. Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group. J Clin Oncol 26 (2008), 4883–4890.
9. 9 Robertson, JFR, Fulvestrant (faslodex)—how to make a good drug better. Oncologist 12 (2007), 774–784.
10. 10 European Medicines Agency. Fulvestrant summary of product characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000540/WC500021174.pdf, 2015 (accessed Sept 8, 2015).
11. 11 US Food and Drugs Administration. Fulvestrant prescribing information. http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021344s015lbl.pdf, 2015 (accessed Aug 30, 2015).
12. 12 Di Leo, A, Jerusalem, G, Petruzelka, L, et al. Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. J Clin Oncol 28 (2010), 4594–4600.
13. 13 Di Leo, A, Jerusalem, G, Petruzelka, L, et al. Final overall survival: fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial. J Natl Cancer Inst, 106, 2014, djt337.
14. 14 Robertson, JF, Llombart-Cussac, A, Rolski, J, et al. Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study. J Clin Oncol 27 (2009), 4530–4535.
15. 15 Robertson, JF, Lindemann, JP, Llombart-Cussac, A, et al. Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized ‘FIRST’ study. Breast Cancer Res Treat 136 (2012), 503–511.
16. 16 Ellis, MJ, Llombart-Cussac, A, Feltl, D, et al. Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: overall survival analysis from the phase II FIRST study. J Clin Oncol 33 (2015), 3781–3787.
17. 17 Brady, MJ, Cella, DF, Mo, F, et al. Reliability and validity of the functional assessment of cancer therapy—breast quality-of-life instrument. J Clin Oncol 15 (1997), 974–986.
18. 18 Burman, CF, Sonesson, C, Guilbaud, O, A recycling framework for the construction of Bonferroni-based multiple tests. Stat Med 28 (2009), 739–761.
19. 19 Ellis, S, Carroll, KJ, Pemberton, K, Analysis of duration of response in oncology trials. Contemp Clin Trials 29 (2008), 456–465.
20. 20 Martin, M, Lopez-Tarruella, S, Gilarranz, YJ, Endocrine therapy for hormone treatment-naive advanced breast cancer. Breast 28 (2016), 161–166.
21. 21 Li, S, Shen, D, Shao, J, et al. Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. Cell Rep 4 (2013), 1116–1130.
22. 22 Fribbens, C, O'Leary, B, Kilburn, L, et al. Plasma ESR1 mutations and the treatment of estrogen receptor-positive advanced breast cancer. J Clin Oncol 34 (2016), 2961–2968.
23. 23 Finn, RS, Martin, M, Rugo, HS, et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med 375 (2016), 1925–1936.
24. 24 Hortobagyi, GN, Stemmer, SM, Burris, HA, et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med 375 (2016), 1738–1748.
25. 25 Zafar, SY, Peppercorn, JM, Schrag, D, et al. The financial toxicity of cancer treatment: a pilot study assessing out-of-pocket expenses and the insured cancer patient's experience. Oncologist 18 (2013), 381–390.